86 research outputs found

    Communications Biophysics

    Get PDF
    Contains reports on four research projects.National Institutes of Health (Grant 5 P01 NS13126-02)National Institutes of Health (Grant 5 K04 NS00113-03)National Institutes of Health (Grant 2 ROI NS11153-02A1)National Science Foundation (Grant BNS77-16861)National Institutes of Health (Grant 5 RO1 NS10916-03)National Institutes of Health (Fellowship 1 F32 NS05327)National Institutes of Health (Grant 5 ROI NS12846-02)National Institutes of Health (Fellowship 1 F32 NS05266)Edith E. Sturgis FoundationNational Institutes of Health (Grant 1 R01 NS11680-01)National Institutes of Health (Grant 2 RO1 NS11080-04)National Institutes of Health (Grant 5 T32 GIM107301-03)National Institutes of Health (Grant 5 TOI GM01555-10

    Ray-optical transformation optics with ideal thin lenses makes omnidirectional lenses

    Get PDF
    We present the theory of ray-optical transformation optics (RTO) with ideal thin lenses, and show that ideal-thin-lens RTO devices are omnidirectional lenses. Key to designing such devices are two theorems, the loop-imaging theorem and the edge-imaging theorem, which ensure that the interior physical space is distorted in the same way for all viewing directions. We discuss the possibility of realising such devices using lens holograms or Fresnel lenses, as both are in principle capable of changing the directions of rays incident from a specific point precisely like an ideal thin lens, thereby enabling macroscopic and broad-band RTO devices that work for at least one viewing position. Even when restricted in this way, our work opens up new possibilities in ray optics. Our devices have the potential to form the basis of new microscope objectives, virtual-reality headsets, and medical spectacles

    Na sombra do Vietnã: o nacionalismo liberal e o problema da guerra

    Full text link

    Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

    Get PDF
    Background The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from routine practice is needed to complement the data from the pivotal trials. Methods OPTIPARK (NCT02847442) was a prospective, open-label, single-arm trial conducted in Germany and the UK under clinical practice conditions. Patients with Parkinson’s disease and motor fluctuations were treated with opicapone 50 mg for 3 (Germany) or 6 (UK) months in addition to their current levodopa and other antiparkinsonian treatments. The primary endpoint was the Clinician’s Global Impression of Change (CGI-C) after 3 months. Secondary assessments included Patient Global Impressions of Change (PGI-C), the Unified Parkinson’s Disease Rating Scale (UPDRS), Parkinson’s Disease Questionnaire (PDQ-8), and the Non-Motor Symptoms Scale (NMSS). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). Results Of the 506 patients enrolled, 495 (97.8%) took at least one dose of opicapone. Of these, 393 (79.4%) patients completed 3 months of treatment. Overall, 71.3 and 76.9% of patients experienced any improvement on CGI-C and PGI-C after 3 months, respectively (full analysis set). At 6 months, for UK subgroup only (n = 95), 85.3% of patients were judged by investigators as improved since commencing treatment. UPDRS scores at 3 months showed statistically significant improvements in activities of daily living during OFF (mean ± SD change from baseline: − 3.0 ± 4.6, p < 0.0001) and motor scores during ON (− 4.6 ± 8.1, p < 0.0001). The mean ± SD improvements of − 3.4 ± 12.8 points for PDQ-8 and -6.8 ± 19.7 points for NMSS were statistically significant versus baseline (both p < 0.0001). Most of TEAEs (94.8% of events) were of mild or moderate intensity. TEAEs considered to be at least possibly related to opicapone were reported for 45.1% of patients, with dyskinesia (11.5%) and dry mouth (6.5%) being the most frequently reported. Serious TEAEs considered at least possibly related to opicapone were reported for 1.4% of patients. Conclusions Opicapone 50 mg was effective and generally well-tolerated in PD patients with motor fluctuations treated in clinical practice. Trial registration Registered in July 2016 at clinicaltrials.gov (NCT02847442)

    Longitudinal Modeling of Frame Changing and Media Salience: Coverage of Worker Displacement, 1980–2007

    No full text
    This article presents the results of a longitudinal analysis of media framing of worker displacement in the United States. To identify the frame-changing dynamic occurring over time, a content analysis was performed on 1,128 articles covering layoffs in The New York Times between 1980 and 2007. The article identifies both frame changing along the time and space dimensions, and changes in core frames of coverage. It also examines the relationship between these framing dynamics and the portrayal of layoffs as either problematic or non-problematic. Ultimately, the article contributes to the potential for convergence between social problems agenda tracking in communication and sociological research, and to the study of media framing of worker displacement, specifically layoffs
    • …
    corecore